Biokit S A Pharmaceutical Import Profile — Spain (DGFT 2022–2026)

Name: Biokit S A Pharmaceutical Import Records from India — 2 Products, $790.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biokit S A — Pharmaceutical Importer Profile (2026) | 2 Products, $790.8K Trade | TransData Nexus

Biokit S A

Pharmaceutical Importer · Spain · Medical Devices & Diagnostics Focus · $790.8K Total Trade · DGFT Verified

Biokit S A is a pharmaceutical importer based in Spain with a total trade value of $790.8K across 2 products in 1 therapeutic categories. Based on 1,718 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Biokit S A sources from 2 verified Indian suppliers, with Yashraj Biotechnology Limited accounting for 64.3% of imports.

Biokit S A — Import Portfolio & Supplier Network

Biokit S A import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Biokit S A?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Yashraj Biotechnology Limited	$352.0K	19	64.3%
Advy Chemical Private Limited	$195.5K	722	35.7%

Biokit S A sources from 2 verified Indian suppliers across .

What Formulations Does Biokit S A Import?

Formulation	Value	Ships
Diagnostic reagents heat inactivated hbsag conc	$130.7K	272
Hepatitis b surface antigen hbsag -	$100.0K	4
Hepatitis b surface antigen hbsag ay4251 00ML laboratory raw material to beused to make in vitro diagnostic	$50.0K	1
Hepatitis b surface antigen hbsag ay4928 00ML laboratory raw material to beused to make in vitro diagnostic	$50.0K	1
Hepatitis b surface antigen hbsag ay5015 00ML laboratory raw material to beused to make in vitro diagnostic	$50.0K	1
Hepatitis b surface antigen hbsag -	$50.0K	1
Diagnostic reagents heat inactivated	$37.5K	71
Hepatitis b surface antigen hbsag laboratory raw material to be used to makein vitro diagnostic control 3241 00 ML	$37.3K	1
Diagnostic reagents heat inactivated	$27.2K	37
Hepatitis b surface antigen hbsag -	$14.7K	1
Diagnostic reagents hbsag concentrate	$61	1
Hepatitis b surface antigen hbsag laboratory row material to be used to makein vitro diagnostic control 22ML	$1	1
Hepatitis b surface antigen hbsag laboratory row material to be used to makein vitro diagnostic control 48 ML	$1	1
Hepatitis b surface antigen hbsag ay42 00ML laboratory raw material to be used to make in vitro diagnostic	$0	1
Hepatitis b surface antigen hbsag 22 00ML laboratory raw material to be used to make in vitro diagnostic control	$0	1

Biokit S A imports 20 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diagnostic	Medical Devices & Diagnostics	$451.2K	732	2.4%	5
2	Reagent	Medical Devices & Diagnostics	$339.6K	986	1.5%	9

Biokit S A imports 2 pharmaceutical products across 1 categories into Spain totaling $790.8K.

Biokit S A — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Biokit S.A., established in 1973, is a Spanish company specializing in the research, development, manufacture, and distribution of clinical diagnostic reagents and systems. Headquartered in Lliçà d'Amunt, Barcelona, the company operates under the Werfen Group, a global leader in in vitro diagnostics. Biokit offers a comprehensive range of products, including immunoassay systems, reagents, and raw materials such as native and recombinant antigens, monoclonal and polyclonal antibodies, and sera. These products are utilized in various diagnostic fields, including infectious diseases, plasma proteins, and coagulation markers.

In addition to its manufacturing capabilities, Biokit S.A. is involved in the distribution of its products both domestically and internationally. The company's strategic focus on high-quality diagnostic solutions has positioned it as a significant player in the clinical diagnostics sector. Biokit S.A. maintains a strong presence in Spain's pharmaceutical distribution network, supplying essential diagnostic reagents to healthcare facilities nationwide.

2Distribution Network

Biokit S.A. operates its distribution network primarily from its headquarters in Lliçà d'Amunt, Barcelona. The company's logistics capabilities are designed to ensure efficient delivery of diagnostic products across Spain. While specific details about additional warehouse locations are not publicly disclosed, Biokit S.A. is known to export its products to numerous countries, indicating a robust international distribution network.

3Industry Role

Biokit S.A. plays a pivotal role in Spain's pharmaceutical supply chain as a manufacturer and distributor of clinical diagnostic reagents and systems. The company is not a wholesaler or parallel importer; instead, it focuses on the production and direct distribution of its proprietary diagnostic products. This direct approach allows Biokit S.A. to maintain control over product quality and distribution, ensuring that healthcare facilities receive reliable and effective diagnostic solutions.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Biokit S A

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Biokit S.A.'s sourcing strategy reveals a significant concentration in its supplier base, with two primary suppliers accounting for the majority of its imports from India. Yashraj Biotechnology Limited supplied products worth $352,000 across 19 shipments, representing 64.3% of the total import value, while Advy Chemical Private Limited provided products totaling $195,000 over 722 shipments, accounting for 35.7%. This concentration suggests a strategic choice to establish strong, long-term relationships with these suppliers, potentially leading to favorable terms and consistent product quality.

However, such dependency also introduces risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by these suppliers. The high number of shipments from Advy Chemical Private Limited indicates a reliance on smaller, more frequent deliveries, which could be vulnerable to logistical challenges. To mitigate these risks, Biokit S.A. may consider diversifying its supplier base and exploring alternative sourcing options.

2Supply Chain Resilience

Biokit S.A.'s supply chain resilience is influenced by its concentrated sourcing from two primary Indian suppliers. The company's reliance on Yashraj Biotechnology Limited and Advy Chemical Private Limited means that any disruptions affecting these suppliers could impact Biokit S.A.'s ability to meet domestic and international demand. The frequent shipments from Advy Chemical Private Limited suggest a just-in-time inventory approach, which, while efficient, may reduce buffer stock levels and increase vulnerability to supply chain interruptions.

Importing Pharmaceuticals into Spain — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Spain

1Regulatory Authority & Framework

In Spain, the Spanish Agency of Medicines and Medical Devices (AEMPS) is the primary regulatory authority overseeing the importation and distribution of medicinal products and medical devices. The AEMPS enforces regulations to ensure the quality, safety, and efficacy of pharmaceutical products within Spain.

The legal framework governing pharmaceutical imports includes Royal Legislative Decree 1/2015, which consolidates laws related to the guarantees and rational use of medicines and healthcare products. Specifically, Articles 72 and 73 address the import and export of medicinal products. Additionally, Royal Decree 824/2010 regulates pharmaceutical laboratories, manufacturers of active substances, and the foreign trade of medicines, establishing conditions for the import, manufacturing, and export of medicines. (administracion.gob.es)

2Import Licensing & GMP

Importers of pharmaceutical products in Spain must obtain authorization from the AEMPS, ensuring compliance with Good Manufacturing Practice (GMP) standards. The AEMPS recognizes GMP certificates from the European Union, the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the importation of medicines that meet these standards.

To distribute medicines within Spain, companies must hold a wholesale distribution authorization granted by the AEMPS. This authorization ensures that distributors adhere to the necessary regulatory requirements and maintain the integrity of the pharmaceutical supply chain. (administracion.gob.es)

Biokit S A — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Biokit S.A.'s focus on diagnostic products, particularly in the fields of infectious diseases, plasma proteins, and coagulation markers, aligns with the growing demand for accurate and timely diagnostic solutions in Spain. The company's product strategy is driven by the need to provide healthcare professionals with reliable tools to make informed clinical decisions, thereby improving patient outcomes.

The importation of finished pharmaceutical formulations from India, such as diagnostic reagents and systems, supports Biokit S.A.'s commitment to offering a comprehensive range of diagnostic solutions. This strategy enables the company to leverage India's manufacturing capabilities and expertise in producing high-quality diagnostic products, ensuring that Biokit S.A. remains competitive in the market.

2Sourcing Profile

Biokit S.A. sources generic diagnostic reagents and systems from India, focusing on finished pharmaceutical formulations rather than active pharmaceutical ingredients (APIs) or bulk drugs. This sourcing strategy allows the company to provide ready-to-use diagnostic solutions to healthcare facilities, meeting the immediate needs of the market. India's established pharmaceutical manufacturing industry offers a reliable supply of high-quality diagnostic products, making it a strategic partner for Biokit S.A.

3Market Positioning

Seller's Guide — How to Become a Supplier to Biokit S A

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Biokit S.A.'s supply chain, particularly if they can offer high-quality diagnostic products that meet the regulatory standards required by the AEMPS. Gaps in Biokit S.A.'s current sourcing may include specific diagnostic assays or reagents that are in high demand but not currently available through existing suppliers. By identifying these gaps and providing innovative solutions, new suppliers can position themselves as valuable partners to Biokit S.A.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Biokit S A

What products does Biokit S A import from India?

Biokit S A imports 2 pharmaceutical products across 1 categories. Top imports: Diagnostic ($451.2K), Reagent ($339.6K).

Who supplies pharmaceuticals to Biokit S A from India?

Biokit S A sources from 2 verified Indian suppliers. The primary supplier is Yashraj Biotechnology Limited (64.3% of imports, $352.0K).

What is Biokit S A's total pharmaceutical import value?

Biokit S A's total pharmaceutical import value from India is $790.8K, based on 1,718 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Biokit S A focus on?

Biokit S A imports across 1 categories. The largest: Medical Devices & Diagnostics (100.0%).

Get Full Biokit S A Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.